RNY4

Across TCGA pan-cancer cohorts, RNY4 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated RNY4 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RNY4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNY4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and MESO show a favorable association.

CHOL, THCA, and LUSC are the cancer types where RNY4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.019	0.800	<.001	72	view →
THCA	OS	Tertile	II,III,IV	0.294	0.923	<.001	57	view →
LUSC	OS	Tertile	All	0.294	0.745	<.001	36	view →
KIRP	DFS	Tertile	II,III,IV	0.520	0.765	.002	36	view →
LUAD	DFS	Tertile	All	0.648	0.320	.011	27	view →
PCPG	DFS	Tertile	All	0.752	0.968	<.001	15	view →
LIHC	DFS	Tertile	III,IV	0.133	0.432	.025	15	view →
BLCA	OS	Tertile	IV	0.141	0.573	.034	9	view →
MESO	DFS	Tertile	IV	0.537	0.161	.033	9	view →
UCEC	OS	Median	All	0.904	0.937	.041	4	view →
HNSC	OS	Tertile	III,IV	0.560	0.755	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RNY4–CHOL (OS)

Open the CHOL breakdown →